Monrovia, California-based biopharmaceuticals developer Xencor has filed for an IPO, saying in a filing this morning that it looking to raise up to $69.0M in its initial public offering. Xencor said it is has applied to trade as XNCR on the NASDAQ Stock Market. Xencor's IPO is being underwritten by Credit Suisse, Leerink Swann, and Wedbush PacGrow Life Sciences. Xencor's backers include MedImmune Ventures, HealthCare Ventures, and investor John R. Stafford, III. Xencor, which is led by Bassil Dahiyat, develops engineered monoclonal antibodies, which are being used to treat autoimmune and allergic diseases, cancer and other conditions.